|
1
|
Mita AC, Mita MM, Nawrocki ST and Giles
FJ: Survivin: key regulator of mitosis and apoptosis and novel
target for cancer therapeutics. Clin Cancer Res. 14:5000–5005.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
McKenzie JA, Liu T, Goodson AG and
Grossman D: Survivin enhances motility of melanoma cells by
supporting Akt activation and α5 integrin upregulation. Cancer Res.
70:7927–7937. 2010.PubMed/NCBI
|
|
3
|
Zhang M, Coen JJ, Suzuki Y, et al:
Survivin is a potential mediator of prostate cancer metastasis. Int
J Radiat Oncol Biol Phys. 78:1095–1103. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Abdraboh ME, Gaur RL, Hollenbach AD,
Sandquist D, Raj MH and Ouhtit A: Survivin is a novel target of
CD44-promoted breast tumor invasion. Am J Pathol. 179:555–563.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhonghong L, Lianjie L, Changqing Z, Ying
H, Yu J and Yan L: The influence of survivin shRNA on the cell
cycle and the invasion of SW480 cells of colorectal carcinoma. J
Exp Clin Cancer Res. 27:202008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chu XY, Chen LB, Wang JH, et al:
Overexpression of survivin is correlated with increased invasion
and metastasis of colorectal cancer. J Surg Oncol. 105:520–528.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen P and Parks WC: Role of matrix
metalloproteinases in epithelial migration. J Cell Biochem.
108:1233–1243. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ii M, Yamamoto H, Adachi Y, Maruyama Y and
Shinomura Y: Role of matrix metalloproteinase-7 (matrilysin) in
human cancer invasion, apoptosis, growth, and angiogenesis. Exp
Biol Med (Maywood). 231:20–27. 2006.PubMed/NCBI
|
|
9
|
Wang FQ, So J, Reierstad S and Fishman DA:
Matrilysin (MMP-7) promotes invasion of ovarian cancer cells by
activation of progelatinase. Int J Cancer. 114:19–31. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Lynch CC, Hikosaka A, Acuff HB, et al:
MMP-7 promotes prostate cancer-induced osteolysis via the
solubilization of RANKL. Cancer Cell. 7:485–496. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shi M, Liu D, Duan H, et al: Catecholamine
up-regulates MMP-7 expression by activating AP-1 and STAT3 in
gastric cancer. Mol Cancer. 9:2692010.PubMed/NCBI
|
|
12
|
Sizemore ST and Keri RA: The forkhead box
transcription factor FOXC1 promotes breast cancer invasion by
inducing matrix metalloprotease 7 (MMP7) expression. J Biol Chem.
287:24631–24640. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Miyamoto S, Yano K, Sugimoto S, et al:
Matrix metalloproteinase-7 facilitates insulin-like growth factor
bioavailability through its proteinase activity on insulin-like
growth factor binding protein 3. Cancer Res. 64:665–671. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ho BY, Wu YM, Chang KJ and Pan TM:
Dimerumic acid inhibits SW620 cell invasion by attenuating
H2O2-mediated MMP-7 expression via JNK/C-Jun
and ERK/C-Fos activation in an AP-1-dependent manner. Int J Biol
Sci. 7:869–880. 2011.PubMed/NCBI
|
|
15
|
Lee SK, Han YM, Yun J, et al: Phosphatase
of regenerating liver-3 promotes migration and invasion by
upregulating matrix metalloproteinases-7 in human colorectal cancer
cells. Int J Cancer. 131:E190–E203. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wang WS, Chen PM, Wang HS, Liang WY and Su
Y: Matrix metalloproteinase-7 increases resistance to Fas-mediated
apoptosis and is a poor prognostic factor of patients with
colorectal carcinoma. Carcinogenesis. 27:1113–1120. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Koskensalo S, Louhimo J, Nordling S,
Hagström J and Haglund C: MMP-7 as a prognostic marker in
colorectal cancer. Tumour Biol. 32:259–264. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fang YJ, Lu ZH, Wang GQ, et al: Elevated
expressions of MMP7, TROP2, and survivin are associated with
survival, disease recurrence, and liver metastasis of colon cancer.
Int J Colorectal Dis. 24:875–884. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang GQ, Lu ZH, Fang YJ, Chen G, Zhou ZW,
Pan ZZ and Wan DS: Expression and clinical significance of survivin
and matrix metalloproteinase-7 in colon cancer. Ai Zheng.
28:945–949. 2009.(In Chinese).
|
|
20
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
|
21
|
Kelley RK, Wang G and Venook AP: Biomarker
use in colorectal cancer therapy. J Natl Compr Canc Netw.
9:1293–1302. 2011.PubMed/NCBI
|
|
22
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Erkanli S, Bolat F, Kayaselcuk F, Demirhan
B and Kuscu E: COX-2 and survivin are overexpressed and positively
correlated in endometrial carcinoma. Gynecol Oncol. 104:320–325.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pennati M, Folini M and Zaffaroni N:
Targeting survivin in cancer therapy: fulfilled promises and open
questions. Carcinogenesis. 28:1133–1139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wu JB, Nan QZ, Ma GF, et al: Short hairpin
RNA-mediated survivin gene silencing inhibits invasion and
metastasis of human colon carcinoma cell line SW480 in vitro. Nan
Fang Yi Ke Da Xue Xue Bao. 27:951–954. 2007.(In Chinese).
|
|
26
|
Church DN and Talbot DC: Survivin in solid
tumors: rationale for development of inhibitors. Curr Oncol Rep.
14:120–128. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Kelly RJ, Lopez-Chavez A, Citrin D, Janik
JE and Morris JC: Impacting tumor cell-fate by targeting the
inhibitor of apoptosis protein survivin. Mol Cancer. 10:352011.
View Article : Google Scholar : PubMed/NCBI
|
